- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03822468
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of a reduced ribociclib dose of 400 mg in combination with an NSAI (letrozole or anastrozole) for the treatment of pre- and postmenopausal women with HR-positive, HER2-negative aBC who have received no prior therapy for advanced disease.
Patients will be randomly assigned to one of the below treatment arms in a 1:1 ratio:
- Experimental arm - Ribociclib 400 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women)
- Control arm - Ribociclib 600 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women).
Participants will receive study treatment until disease progression (radiologically documented according to RECIST 1.1 criteria), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. Continuation of study treatment beyond initial disease progression (RECIST 1.1) will not be allowed.
For participants who discontinue treatment for reasons other than documented disease progression, death, lost to follow-up, or withdrawal of consent, tumor assessments must continue to be performed until disease progression, death, lost to follow-up, or withdrawal of consent (post-treatment efficacy follow-up).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Argentina, J5402DIL
- Novartis Investigative Site
-
-
-
-
-
Innsbruck, Austria, A-6020
- Novartis Investigative Site
-
Linz, Austria, 4010
- Novartis Investigative Site
-
Salzburg, Austria, 5020
- Novartis Investigative Site
-
Vienna, Austria, 1090
- Novartis Investigative Site
-
-
-
-
-
Namur, Belgium, 5000
- Novartis Investigative Site
-
-
Antwerpen
-
Edegem, Antwerpen, Belgium, 2650
- Novartis Investigative Site
-
-
-
-
-
Sao Jose do Rio Preto, Brazil, 15090 000
- Novartis Investigative Site
-
-
GO
-
Goiania, GO, Brazil, 74605-070
- Novartis Investigative Site
-
-
RN
-
Natal, RN, Brazil, 59075 740
- Novartis Investigative Site
-
-
SP
-
Sao Paulo, SP, Brazil, 04014-002
- Novartis Investigative Site
-
Sao Paulo, SP, Brazil, 01317 000
- Novartis Investigative Site
-
-
Santa Catarina
-
Florianopolis, Santa Catarina, Brazil, 88034 000
- Novartis Investigative Site
-
-
-
-
-
Plovdiv, Bulgaria, 4004
- Novartis Investigative Site
-
Sofia, Bulgaria, 1756
- Novartis Investigative Site
-
Sofia, Bulgaria, 1303
- Novartis Investigative Site
-
-
-
-
Ontario
-
Cambridge, Ontario, Canada, N1R 3G2
- Novartis Investigative Site
-
-
-
-
-
Bogota, Colombia, 110221
- Novartis Investigative Site
-
Bogota, Colombia, 110131
- Novartis Investigative Site
-
Monteria, Colombia, 230002
- Novartis Investigative Site
-
-
Cesar
-
Valledupar, Cesar, Colombia, 5602310
- Novartis Investigative Site
-
-
Tolima
-
Ibague, Tolima, Colombia, 730006
- Novartis Investigative Site
-
-
-
-
-
San Jose, Costa Rica, 95008
- Novartis Investigative Site
-
-
-
-
-
Praha 5, Czechia, 150 06
- Novartis Investigative Site
-
-
Czech Republic
-
Brno, Czech Republic, Czechia, 656 53
- Novartis Investigative Site
-
-
-
-
-
Helsinki, Finland, 00029
- Novartis Investigative Site
-
Tampere, Finland, FIN-33521
- Novartis Investigative Site
-
-
-
-
-
Besancon Cedex, France, 25030
- Novartis Investigative Site
-
Caen, France, 14021
- Novartis Investigative Site
-
Clermont Ferrand, France, 63011
- Novartis Investigative Site
-
Lyon Cedex 08, France, 69373
- Novartis Investigative Site
-
Marseille, France, 13273
- Novartis Investigative Site
-
Montpellier, France, 34298
- Novartis Investigative Site
-
Saint Herblain, France, 44805
- Novartis Investigative Site
-
Strasbourg, France, F 67085
- Novartis Investigative Site
-
Valenciennes, France, 59300
- Novartis Investigative Site
-
-
-
-
-
Augsburg, Germany, 86150
- Novartis Investigative Site
-
Berlin, Germany, 13581
- Novartis Investigative Site
-
Bonn, Germany, 53111
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Novartis Investigative Site
-
Dresden, Germany, 01127
- Novartis Investigative Site
-
Essen, Germany, 45136
- Novartis Investigative Site
-
Tuebingen, Germany, 72076
- Novartis Investigative Site
-
Weiden, Germany, 92637
- Novartis Investigative Site
-
-
Hessen
-
Langen, Hessen, Germany, 63225
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, H 1122
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Novartis Investigative Site
-
Szolnok, Hungary, H-5000
- Novartis Investigative Site
-
-
-
-
-
Delhii, India, 110 085
- Novartis Investigative Site
-
Mumbai, India, 400 012
- Novartis Investigative Site
-
-
Chhattisgarh
-
Raipur, Chhattisgarh, India, 492001
- Novartis Investigative Site
-
-
Maharashtra
-
Nagpur, Maharashtra, India, 441108
- Novartis Investigative Site
-
-
Orissa
-
Bhubaneshwar, Orissa, India, 751007
- Novartis Investigative Site
-
-
-
-
-
Amman, Jordan, 11941
- Novartis Investigative Site
-
-
-
-
-
Vilnius, Lithuania, LT-08660
- Novartis Investigative Site
-
-
LTU
-
Kaunas, LTU, Lithuania, LT 50161
- Novartis Investigative Site
-
-
-
-
La Libertad
-
Trujillo, La Libertad, Peru, 13011
- Novartis Investigative Site
-
-
Lima
-
San Borja, Lima, Peru, 41
- Novartis Investigative Site
-
San Isidro, Lima, Peru, 27
- Novartis Investigative Site
-
San Miguel, Lima, Peru, 32
- Novartis Investigative Site
-
-
-
-
-
Lisbon, Portugal, 1400 038
- Novartis Investigative Site
-
Loures, Portugal, 2674514
- Novartis Investigative Site
-
Porto, Portugal, 4200-072
- Novartis Investigative Site
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
- Novartis Investigative Site
-
Moscow, Russian Federation, 115478
- Novartis Investigative Site
-
Moscow, Russian Federation, 111123
- Novartis Investigative Site
-
St Petersburg, Russian Federation, 197758
- Novartis Investigative Site
-
St Petersburg, Russian Federation, 189646
- Novartis Investigative Site
-
-
-
-
-
Cape Town, South Africa, 7500
- Novartis Investigative Site
-
Johannesburg, South Africa, 2196
- Novartis Investigative Site
-
Parktown, South Africa, 2193
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Sweden, SE-118 83
- Novartis Investigative Site
-
Stockholm, Sweden, 112 19
- Novartis Investigative Site
-
Uppsala, Sweden, 751 85
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Novartis Investigative Site
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Southern Cancer Center PC .
-
-
California
-
Greenbrae, California, United States, 94904
- Marin Cancer Care
-
-
Colorado
-
Longmont, Colorado, United States, 80501
- Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50)
-
-
Florida
-
Orlando, Florida, United States, 32804
- Florida Retina Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21237-3998
- Weinberg Cancer Institute at Franklin Square Hospital
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Nebraska Hematology-Oncology, P.C.
-
Omaha, Nebraska, United States, 68154
- Nebraska Cancer Specialists Oncology Hematology West
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4)
-
-
New York
-
Albany, New York, United States, 12208
- New York Oncology Hematology SC
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine CFTY720D2306
-
-
Texas
-
Houston, Texas, United States, 77090
- Millennium Research Clin Develop .
-
McAllen, Texas, United States, 78503
- Texas Oncology
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Northwest Medical Specialties Dept.ofNW Med. Specialties
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key inclusion criteria:
- Patient has advanced (loco-regionally recurrent or metastatic) breast cancer not amenable to curative therapy.
- Patient has a histologically and/or cytologically confirmed diagnosis of ER-positive and/or PgR-positive breast cancer based on the most recently analyzed tissue sample, and all tested by local laboratory.
- Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample.
- Patient must have measurable disease, i.e., at least one measurable lesion according to RECIST version 1.1. (a lesion in a previously irradiated site may only be counted as a target lesion if there is clear evidence of progression since the irradiation).
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed by the central laboratory:
- QTcF interval at screening < 450 ms (QT interval using Fridericia's correction)
- Mean resting heart rate 50 to 90 bpm (determined from the ECG)
- Women of childbearing potential (CBP), defined as all women physiologically capable of becoming pregnant, must have confirmed negative serum pregnancy test (for β-hCG) within 14 days prior to randomization.
- Women of CBP must be willing to use highly effective methods of contraception.
Key Exclusion Criteria:
- Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's judgment.
- Patient who received any prior systemic anti-cancer therapy(including endocrine therapy, chemotherapy, prior CDK4/6 inhibitors) for aBC. Patients who received neo-/adjuvant therapy for breast cancer are eligible.
- Patient is concurrently using other anti-cancer therapy.
- Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major toxicities.
- Patient has received extended-field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to randomization, and has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). Patients in whom ≥
- 25% of the bone marrow has been previously irradiated are also excluded.
- Patient has a concurrent malignancy or malignancy within 3 years of the randomization date, with the exception of adequately treated basal or squamous cell skin carcinoma, or curatively resected cervical carcinoma in situ.
- Patients with central nervous system (CNS) involvement unless they meet specific stability criteria.
- Patient has clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
- Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting study drug, and has not fully recovered from side effects of such treatment.
Other protocol-defined Inclusion/Exclusion may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ribociclib 400 mg
Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
|
Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28).
Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Other Names:
Anastrozole 1 mg tablets for oral use QD continuously
Letrozole 2.5 mg tablets for oral use QD continuously
|
Active Comparator: Ribociclib 600 mg
Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
|
Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28).
Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Other Names:
Anastrozole 1 mg tablets for oral use QD continuously
Letrozole 2.5 mg tablets for oral use QD continuously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 23.8 months
|
ORR defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by local investigators according to RECIST 1.1. CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. |
Up to 23.8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in QTc (With Fridericia's Correction) at Cycle 1 Day 15 (at 2 Hours Post-dose)
Time Frame: Baseline and Cycle 1 Day 15 at 2 hours post-dose. Cycle = 28 days
|
Electrocardiogram (ECG) data was collected via 12-lead digital ECG machines.
Change from baseline in the QT interval (a segment of the ECG that reflects the time it takes for the heart to repolarize after each heartbeat) was corrected for heart rate using Fridericia's formula (ΔQTcF).
|
Baseline and Cycle 1 Day 15 at 2 hours post-dose. Cycle = 28 days
|
Progression-free Survival (PFS)
Time Frame: Up to approximately 60 months
|
PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason.
PFS will be assessed via a local radiology assessment as well as BIRC according to RECIST 1.1.
|
Up to approximately 60 months
|
Clinical Benefit Rate (CBR)
Time Frame: Up to approximately 60 months
|
CBR is defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR), or an overall response of stable disease (SD), lasting for at least 24 weeks. CR, PR, and SD are defined as per local review as well as BIRC according to RECIST 1.1. CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease. |
Up to approximately 60 months
|
Time to Response (TTR)
Time Frame: Up to approximately 60 months
|
TTR defined as defined as the time from the date of randomization to the first documented response of either CR or PR. CR and PR are based on tumor response data as per local review and according to RECIST 1.1. CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. |
Up to approximately 60 months
|
Duration of Response (DOR)
Time Frame: Up to approximately 60 months
|
DOR defined as the time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer. CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. |
Up to approximately 60 months
|
Pharmacokinetics (PK) of Ribociclib: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
PK parameters were calculated by non-compartmental analysis.
Cmax is the maximum observed plasma drug concentration after single dose administration.
|
Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
PK of Ribociclib: Time to Reach Observed Maximum Concentration (Tmax)
Time Frame: Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
PK parameters were calculated by non-compartmental analysis.
Tmax is the time to reach maximum observed plasma concentration.
Actual recorded sampling times were considered for the calculations.
|
Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
PK of Ribociclib: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24)
Time Frame: Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
PK parameters were calculated by non-compartmental analysis.
AUC0-24 is the area under the plasma concentration-time curve from 0 to 24 hours
|
Cycle 1 Day 15 at pre-dose, and 2, 4, 6 and 24 hours post-dose. Cycle = 28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Goserelin
- Anastrozole
Other Study ID Numbers
- CLEE011A2207
- 2018-004234-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Goserelin
-
CMX ResearchPeptigroupe Inc.CompletedProstate CancerCanada, Georgia
-
Xiangyun ZongZhejiang Cancer HospitalCompletedBreast CancerChina
-
Tampere UniversityFinnish Prostate Cancer GroupUnknownPatients With T1-4 Advanced Prostate CancerFinland
-
Eurofarma Laboratorios S.A.Recruiting
-
Peking University People's HospitalUnknownInfertility Associated With Endometriosis
-
AstraZenecaCompletedAdvanced Breast CancerRussian Federation, Ukraine, Czech Republic
-
Seattle Institute for Biomedical and Clinical ResearchUnited States Department of Defense; University of WashingtonActive, not recruitingMetastatic Prostate Cancer | Androgen Deprivation TherapyUnited States
-
AstraZenecaCompleted
-
Peking University People's HospitalRecruiting
-
424 General Military HospitalAristotle University Of Thessaloniki; 251 Hellenic Air Force & VA General HospitalCompletedEndometriosis | Bone Density | Muscle | Bone MetabolismGreece